Liangyihui completed Series C financing of over 100 million yuan
Liangyihui.net, an innovative digital medical platform in the oncology field, announced the completion of a Series C financing of over 100 million yuan.
Qiming Venture Partners led this round of financing with participation from DT Capital. Existing investors Redhill Capital, Wang Jiaquan Family Office, Yuanju Capital, and Jiangsu Juhe Capital Management also participated.
HaoYue Capital acted as the exclusive financial advisor.
Founded in 2015, Liangyihui.net has gathered the largest number of online oncology doctors and patients, with nearly 200,000 oncologists and about 300,000 oncology patients.
After 6 years of content-led technological innovation and driven by data, Liangyihui.net has become the No.1 online platform for oncology doctors and patients.
Liangyihui.net provides an innovative digital medical platform for doctors, patients, hospitals, and pharmaceutical companies, which will accurately match all parties’ needs and supplies in the oncology drug treatment process and finally allow oncology patients to receive complete diagnosis and treatment and timely use of drugs.
Since the epidemic, Liangyihui.net has given full play to its platform’s value and organized thousands of free consultation events for patients, which have successfully benefited tens of thousands of patients. During the epidemic, oncologists and patients were connected through this online platform.
Mr. Wang Jue, the founder of Liangyihui.net, said that Liangyihui.net has adhered to and focused on building a professional vertical platform for oncology for many years, bringing together professional participants in all fields.
It is committed to creating the most comprehensive learning platform with IPs for oncologists and providing patients with the most accessible medical services and a complete marketing plan for pharmaceutical companies, he said.